Azithramycine

Azithramycine is a lipid of Polyketides (PK) class. Azithramycine is associated with abnormalities such as Respiratory Tract Infections, Pneumonia, Lower respiratory tract infection, Infection and Nonspecific urethritis. The involved functions are known as Lysis, Selection, Genetic, Mutation, Relapse and Adaptation. Azithramycine often locates in Blood, Respiratory System, Genitourinary system, Back and Chest. The associated genes with Azithramycine are Genes, rRNA, Genome, RPL22 gene, OPRM1 gene and tryptic soy broth. The related lipids are Liposomes, Phosphatidylserines, Promega, Lipopolysaccharides and Steroids. The related experimental models are Mouse Model, Knock-out and Tissue Model.

Cross Reference

Introduction

To understand associated biological information of Azithramycine, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Azithramycine?

Azithramycine is suspected in Infection, Pneumonia, Trachoma, Respiratory Tract Infections, Gonorrhea, Infectious disease of lung and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Azithramycine

MeSH term MeSH ID Detail
Abnormalities, Drug-Induced D000014 10 associated lipids
Abortion, Spontaneous D000022 12 associated lipids
Abscess D000038 13 associated lipids
Achondroplasia D000130 1 associated lipids
Acinetobacter Infections D000151 4 associated lipids
Acne Vulgaris D000152 35 associated lipids
Acquired Immunodeficiency Syndrome D000163 12 associated lipids
Actinomycetales Infections D000193 4 associated lipids
Agammaglobulinemia D000361 4 associated lipids
Airway Obstruction D000402 13 associated lipids
Amebiasis D000562 2 associated lipids
Anaphylaxis D000707 35 associated lipids
Anaplasmataceae Infections D000711 3 associated lipids
Angina, Unstable D000789 14 associated lipids
Aphasia, Broca D001039 1 associated lipids
Arteriosclerosis D001161 86 associated lipids
Arthritis D001168 41 associated lipids
Arthritis, Infectious D001170 8 associated lipids
Bacterial Infections D001424 21 associated lipids
Bartonella Infections D001474 3 associated lipids
Per page 10 20 50 100 | Total 276

PubChem Associated disorders and diseases

What pathways are associated with Azithramycine

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Azithramycine?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Azithramycine?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Azithramycine?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Azithramycine?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Azithramycine?

Mouse Model

Mouse Model are used in the study 'Azithromycin increases in vitro fibronectin production through interactions between macrophages and fibroblasts stimulated with Pseudomonas aeruginosa.' (Cory TJ et al., 2013), Mouse Model are used in the study 'Efficacy of azithromycin, clarithromycin and beta-lactam agents against experimentally induced bronchopneumonia caused by Haemophilus influenzae in mice.' (Miyazaki S et al., 2001), Mouse Model are used in the study 'Oral anti-pneumococcal activity and pharmacokinetic profiling of a novel peptide deformylase inhibitor.' (Gross M et al., 2004), Mouse Model are used in the study 'Inhibition of quorum sensing in Pseudomonas aeruginosa by azithromycin and its effectiveness in urinary tract infections.' (Bala A et al., 2011) and Mouse Model are used in the study 'Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models.' (Girard D et al., 2005).

Knock-out

Knock-out are used in the study 'Influence of rhlR and lasR on Polymyxin Pharmacodynamics in Pseudomonas aeruginosa and Implications for Quorum Sensing Inhibition with Azithromycin.' (Bulman ZP et al., 2017) and Knock-out are used in the study 'Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.' (Mulet X et al., 2009).

Tissue Model

Tissue Model are used in the study 'Development of a population pharmacokinetic model characterizing the tissue distribution of azithromycin in healthy subjects.' (Zheng S et al., 2014).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with Azithramycine

Download all related citations
Per page 10 20 50 100 | Total 4404
Authors Title Published Journal PubMed Link
Marco M Opportunistic infections in Vancouver. 1996 GMHC Treat Issues pmid:11363841
Azithromycin effective in preventing MAC. 1996 AIDS Alert pmid:11363857
Schouten JT and Whittemore S Recent development in the treatment and prevention of disseminated Mycobacterium avium complex (MAC). 1996 STEP Perspect pmid:11364267
Wondrack L et al. Clinical strain of Staphylococcus aureus inactivates and causes efflux of macrolides. 1996 Antimicrob. Agents Chemother. pmid:8849266
Girard AE et al. Correlation of increased azithromycin concentrations with phagocyte infiltration into sites of localized infection. 1996 J. Antimicrob. Chemother. pmid:8818842
Girard D et al. Influence of immunosuppression on the pharmacokinetics and pharmacodynamics of azithromycin in infected mouse tissues. 1996 J. Antimicrob. Chemother. pmid:8818843
Foulds G et al. The absence of an effect of food on the bioavailability of azithromycin administered as tablets, sachet or suspension. 1996 J. Antimicrob. Chemother. pmid:8818844
Vaudaux BP et al. Concentrations of azithromycin in tonsilar and/or adenoid tissue from paediatric patients. 1996 J. Antimicrob. Chemother. pmid:8818845
Pukander J and Rautianen M Penetration of azithromycin into middle ear effusions in acute and secretory otitis media in children. 1996 J. Antimicrob. Chemother. pmid:8818846
Rodriguez AF An open study to compare azithromycin with cefaclor in the treatment of children with acute otitis media. 1996 J. Antimicrob. Chemother. pmid:8818847
O'Doherty B An open comparative study of azithromycin versus cefaclor in the treatment of patients with upper respiratory tract infections. 1996 J. Antimicrob. Chemother. pmid:8818848
Müller O An open comparative study of azithromycin and roxithromycin in the treatment of acute upper respiratory tract infections. 1996 J. Antimicrob. Chemother. pmid:8818849
Gris P Once-daily, 3-day azithromycin versus a three-times-daily, 10-day course of co-amoxiclav in the treatment of adults with lower respiratory tract infections: results of a randomized, double-blind comparative study. 1996 J. Antimicrob. Chemother. pmid:8818850
Zachariah J A randomized, comparative study to evaluate the efficacy and tolerability of a 3-day course of azithromycin versus a 10-day course of co-amoxiclav as treatment of adult patients with lower respiratory tract infections. 1996 J. Antimicrob. Chemother. pmid:8818851
Ednie LM et al. Comparative activities of clarithromycin, erythromycin, and azithromycin against penicillin-susceptible and penicillin-resistant pneumococci. 1996 Antimicrob. Agents Chemother. pmid:8843313
Worth S et al. Quality control guidelines for amoxicillin, amoxicillin-clavulanate, azithromycin, piperacillin-tazobactam, roxithromycin, ticarcillin, ticarcillin-clavulanate, trovafloxacin (CP 99,219), U-100592, and U-100766 for various National Committee for Clinical Laboratory Standards susceptibility testing methods. Results from multicenter trials. 1996 Diagn. Microbiol. Infect. Dis. pmid:9147914
Hultén K et al. New pharmacokinetic in vitro model for studies of antibiotic activity against intracellular microorganisms. 1996 Antimicrob. Agents Chemother. pmid:9124830
Marchisio P et al. Comparative study of once-weekly azithromycin and once-daily amoxicillin treatments in prevention of recurrent acute otitis media in children. 1996 Antimicrob. Agents Chemother. pmid:9124831
Meloni G and Meloni T Azithromycin vs. doxycycline for Mediterranean spotted fever. 1996 Pediatr. Infect. Dis. J. pmid:8933556
Tateda K et al. Direct evidence for antipseudomonal activity of macrolides: exposure-dependent bactericidal activity and inhibition of protein synthesis by erythromycin, clarithromycin, and azithromycin. 1996 Antimicrob. Agents Chemother. pmid:8891128
Hunt Gerardo S et al. Comparison of Etest to broth microdilution method for testing Streptococcus pneumoniae susceptibility to levofloxacin and three macrolides. 1996 Antimicrob. Agents Chemother. pmid:8891154
Young LS Treatment and prophylaxis of Mycobacterium avium complex. 1996 Int J STD AIDS pmid:8652724
Hoepelman IM Human cryptosporidiosis. 1996 Int J STD AIDS pmid:8652725
McCutchan JA Azithromycin in the prophylaxis of opportunistic infections in AIDS. 1996 Int J STD AIDS pmid:8652726
Ridgway GL Azithromycin in the management of Chlamydia trachomatis infections. 1996 Int J STD AIDS pmid:8652727
Ballard RC et al. Treatment of chancroid with azithromycin. 1996 Int J STD AIDS pmid:8652728
Bowden FJ et al. Pilot study of azithromycin in the treatment of genital donovanosis. 1996 Genitourin Med pmid:8655160
Kohl PK et al. Gonorrhoea: single-dose oral treatment. 1996 Curr. Probl. Dermatol. pmid:8743257
Nickel P and Näher H Nongonococcal urethritis. 1996 Curr. Probl. Dermatol. pmid:8743259
Johnson RB Azithromycin. 1996 Curr. Probl. Dermatol. pmid:8743269
MashkilleÄ­son AL [The treatment of early syphilis today]. 1996 Ter. Arkh. pmid:9045378
Luke DR et al. Safety, toleration, and pharmacokinetics of intravenous azithromycin. 1996 Antimicrob. Agents Chemother. pmid:8913468
Olsen KM et al. Intrapulmonary pharmacokinetics of azithromycin in healthy volunteers given five oral doses. 1996 Antimicrob. Agents Chemother. pmid:8913469
Kuo CC et al. In vitro activities of azithromycin, clarithromycin, and other antibiotics against Chlamydia pneumoniae. 1996 Antimicrob. Agents Chemother. pmid:8913488
Aoyama T et al. Efficacy of short-term treatment of pertussis with clarithromycin and azithromycin. 1996 J. Pediatr. pmid:8917247
Pacifico L et al. Comparative efficacy and safety of 3-day azithromycin and 10-day penicillin V treatment of group A beta-hemolytic streptococcal pharyngitis in children. 1996 Antimicrob. Agents Chemother. pmid:8849215
Jaruratanasirikul S et al. Distribution of azithromycin into brain tissue, cerebrospinal fluid, and aqueous humor of the eye. 1996 Antimicrob. Agents Chemother. pmid:8851625
Magid D et al. Doxycycline compared with azithromycin for treating women with genital Chlamydia trachomatis infections: an incremental cost-effectiveness analysis. 1996 Ann. Intern. Med. pmid:8554247
Schwartz RA et al. Bacillary angiomatosis in an HIV seronegative patient on systemic steroid therapy. 1996 Br. J. Dermatol. pmid:8977724
Genç M and Mårdh A A cost-effectiveness analysis of screening and treatment for Chlamydia trachomatis infection in asymptomatic women. 1996 Ann. Intern. Med. pmid:7503471
Roord JJ et al. Prospective open randomized study comparing efficacies and safeties of a 3-day course of azithromycin and a 10-day course of erythromycin in children with community-acquired acute lower respiratory tract infections. 1996 Antimicrob. Agents Chemother. pmid:9124837
McCarty J A multicenter, open label trial of azithromycin for the treatment of children with acute otitis media. 1996 Pediatr. Infect. Dis. J. pmid:8878240
Aronovitz G A multicenter, open label trial of azithromycin vs. amoxicillin/ clavulanate for the management of acute otitis media in children. 1996 Pediatr. Infect. Dis. J. pmid:8878241
McLinn S A multicenter, double blind comparison of azithromycin and amoxicillin/ clavulanate for the treatment of acute otitis media in children. 1996 Pediatr. Infect. Dis. J. pmid:8878242
Khurana CM A multicenter, randomized, open label comparison of azithromycin and amoxicillin/clavulanate in acute otitis media among children attending day care or school. 1996 Pediatr. Infect. Dis. J. pmid:8878243
Powers JL Properties of azithromycin that enhance the potential for compliance in children with upper respiratory tract infections. 1996 Pediatr. Infect. Dis. J. pmid:8878244
Wenisch C et al. Effect of single oral dose of azithromycin, clarithromycin, and roxithromycin on polymorphonuclear leukocyte function assessed ex vivo by flow cytometry. 1996 Antimicrob. Agents Chemother. pmid:8878577
Yeates RA et al. Interaction between midazolam and clarithromycin: comparison with azithromycin. 1996 Int J Clin Pharmacol Ther pmid:8880291
Dunn CJ and Barradell LB Azithromycin. A review of its pharmacological properties and use as 3-day therapy in respiratory tract infections. 1996 Drugs pmid:8882383
Gnarpe J et al. In vitro activities of azithromycin and doxycycline against 15 isolates of Chlamydia pneumoniae. 1996 Antimicrob. Agents Chemother. pmid:8843291